Letybo was evaluated in three Phase III clinical trials involving 1,271 patients, and it’s FDA-approved as being safe and effective.
In the FDA-reviewed trials, the most common adverse reaction was a headache, reported in 2% of Letybo-treated patients.
Other potential adverse reactions include injection-site reactions and effects related to unintended effects on nearby muscles.
Rarely, any botulinum toxin product can spread beyond the injection site and cause symptoms such as generalized weakness, difficulty swallowing, or difficulty breathing. These symptoms may occur hours to weeks after injection and can be serious. Follow your provider’s aftercare instructions to help mitigate this potential risk, and seek immediate medical attention if you have symptoms that concern you.
Letybo may not be appropriate for you if you have:
- a known hypersensitivity to Letybo or another botulinum toxin product
- an infection at the planned injection site
- certain neuromuscular disorders
- certain conditions affecting swallowing or breathing
Letybo is not recommended for use in children, pregnant women, or women who are breastfeeding according to the current U.S. prescribing information.
Your injector should determine whether you're a good candidate based on your health history, anatomy, medications, and treatment goals.
RealSelf Tip: The safest way to get a neuromodulator isn't to chase the lowest price or newest product. Choose a qualified medical provider with substantial experience, and make sure you know exactly what product you're receiving.